While DRG1 acts as a cancer-promoting effector in lung adenocarcinoma, melanoma, hepatocellular carcinoma, and cervical adenocarcinoma [26–29], its lower expression was associated with poor survival in breast cancer and colorectal cancer [30, 31]. This evidence concerns the gene DRG1 and breast cancer.